YATHARTHYatharth Hospital & Trauma Care Services Limited
Healthcare · Medical Care Facilities · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Yatharth Hospital & Trauma Care Services Limited, together with its subsidiaries, owns and operates super-specialty hospitals in India. The company offers services in the areas of medicine, cardiology, neurosciences, general surgery, nephrology and urology, pediatrics, gastroenterology, pulmonology, gynecology, orthopedics, spine and rheumatology, plastic and cosmetic surgery, ear, nose, throat, endocrinology, critical care, dermatology, nuclear medicine, and cancer and bone marrow transplant. It also provides services in the areas of GI surgery and liver transplant, robotic surgery, kidney transplant, IVF and fertility, emergency medicine, ophthalmology, dentistry, psychology and psychiatry, physiotherapy and rehabilitation, anesthesiology, radiology, pathology and laboratory medicine, nutrition and health, interventional spine and pain medicine, neurology, neurosurgery, and cardiovascular and thoracic surgery. In addition, the company sells medicines and canteen food. The company was incorporated in 2008 and is based in Noida, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on YATHARTH — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Revenue growth: 44.2% YoY
- • Debt/Equity: 0.15
- • Promoter holding: 56.9%
- • Price vs SMA200: above
- • Golden cross setup: SMA50 above SMA200
- • 3-month return: +11.1%
Bull case
- • Revenue growth: 44.2% YoY
- • Debt/Equity: 0.15
- • Promoter holding: 56.9%
- • Price vs SMA200: above
Bear case
- • ROE: 9.9%
- • ROCE: 10.0%
- • RSI: 36
- • MACD: bearish
Key risks
- • ROE: 9.9%
- • ROCE: 10.0%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹39.98). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.